News

Audacious 2017: 1 million dollars raised to support research against cancer

Montreal, June 1, 2017 — Close to 425 guests joined forces last night at the Caisse de dépôt et placement du Québec’s The Parquet to take part in the 4th edition of the Audacious fundraising event, benefiting the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal. Thanks to their generous contribution, as well as those of our […]

Agreement between the Hebrew University of Jerusalem and the University of Montreal and new collaborations with IRIC

Tel Aviv, May 23, 2017 – As part of his mission to Israel, the Premier of Quebec announced today an agreement between the Hebrew University of Jerusalem and the University of Montreal. It includes the development of new projects in collaboration with the Institute for Research in Immunology and Cancer (IRIC) in the fields of structural biology, molecular pharmacology and drug […]

IRICoR – Business Seminar

Hot topics in Immuno-Oncology and Genetic Therapies
IRICoR, the Institute for Research in Immunology and Cancer – Commercialization of Research of Université de Montréal, in association with Defined Health, a leading business development strategy consulting firm, are pleased to invite you to its Business Seminar.

Date and time: Wednesday, June 14, 2017 at noon
Where : Room S1-151, Jean Coutu Pavilion

Registration is required. […]

IRICoR: a unique model

For the annual edition of the Canadian Society for Pharmaceutical Sciences (CSPS) and the Canadian Chapter of the Controlled Release Society (CC-CRS) conferences, Mrs. Nadine Beauger, Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), was invited to present her organization’s model as Université de Montréal’s key drug discovery and project maturation […]

IRICoR and AstraZeneca enter into Drug Screening and Development Partnership

The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), Université de Montréal’s drug discovery and project maturation unit based at the Institute for Research in Immunology and Cancer (IRIC), whose mandate is to accelerate the discovery, development and commercialization of novel therapies in cancer and related fields, has entered into a strategic collaboration with AstraZeneca, a […]

ExCellThera wins first prize at the HealthKick Challenge

The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is pleased to announce that its clinical-stage spin-off company, ExCellThera, won the $20,000 first prize in the Pharma & Biotech category at the HealthKick Challenge, which took place in Toronto, Ontario, on April 5th.
ExCellThera, the result of IRICoR’s collaboration with the Centre for Commercialization of […]

IRICoR and C3i Announce Partnership to Identify novel Tumor-Specific Antigens (TSAs)

Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i
 
Montreal, April 4, 2017 — The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and the Centre for Commercialization of Cancer Immunotherapy (C3i) are pleased to announce a major collaboration to […]

IRICoR to attend BIO-EUROPE Spring 2017

The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) of Université de Montréal will attend the 11th Annual International Partnering Conference BIO-EUROPE Spring. This conference is being held from March 20 to March 22, 2017 at the CCIB Convention Center in Barcelona, Spain.
For more information about BIO-EUROPE Spring 2017 click here : BIO-EUROPE Spring 2017
For a meeting […]

New antithrombotic drug developed through a research partnership between IRIC and Bristol-Myers Squibb

An article describing the identification and development of a new molecule to treat thrombotic diseases via a partnership with Bristol-Myers Squibb (BMS) was published in the January 4 edition of the prestigious scientific journal Science Translational Medicine.
This molecule, BMS-986120, acts on cellular receptor PAR4 involved in the activation of blood platelets in clot formation. Thus, it reduces considerably […]

IRICoR participates in the Mission économique en Suisse

Mission économique en Suisse : A real success
From January 22 to 26 2017, took place the first Mission économique en Suisse, led by Québec Chief Scientist Mr. Rémi Quirion. Ms. Nadine Beauger, Chief Executive Officer of the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) was part of a group of more than 20 representatives of the […]

Next Page »